Structure, Function, and Applications of the Georgetown–Einstein (GE) Breast Cancer Simulation Model

Clyde B. Schechter, Aimee M. Near, Jinani Jayasekera, Young Chandler, Jeanne S. Mandelblatt

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background. The Georgetown University-Albert Einstein College of Medicine breast cancer simulation model (Model GE) has evolved over time in structure and function to reflect advances in knowledge about breast cancer, improvements in early detection and treatment technology, and progress in computing resources. This article describes the model and provides examples of model applications. Methods. The model is a discrete events microsimulation of single-life histories of women from multiple birth cohorts. Events are simulated in the absence of screening and treatment, and interventions are then applied to assess their impact on population breast cancer trends. The model accommodates differences in natural history associated with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) biomarkers, as well as conventional breast cancer risk factors. The approach for simulating breast cancer natural history is phenomenological, relying on dates, stage, and age of clinical and screen detection for a tumor molecular subtype without explicitly modeling tumor growth. The inputs to the model are regularly updated to reflect current practice. Numerous technical modifications, including the use of object-oriented programming (C++), and more efficient algorithms, along with hardware advances, have increased program efficiency permitting simulations of large samples. Results. The model results consistently match key temporal trends in US breast cancer incidence and mortality. Conclusion. The model has been used in collaboration with other CISNET models to assess cancer control policies and will be applied to evaluate clinical trial design, recurrence risk, and polygenic risk-based screening.

Original languageEnglish (US)
Pages (from-to)66S-77S
JournalMedical Decision Making
Volume38
Issue number1_suppl
DOIs
StatePublished - Apr 1 2018

Fingerprint

Breast Neoplasms
Natural History
Organizational Efficiency
Multiple Birth Offspring
Neoplasms
Estrogen Receptors
Biomarkers
Medicine
Clinical Trials
Technology
Recurrence
Mortality
Incidence
Therapeutics
Growth
Population

Keywords

  • breast cancer
  • simulation modeling

ASJC Scopus subject areas

  • Health Policy

Cite this

Structure, Function, and Applications of the Georgetown–Einstein (GE) Breast Cancer Simulation Model. / Schechter, Clyde B.; Near, Aimee M.; Jayasekera, Jinani; Chandler, Young; Mandelblatt, Jeanne S.

In: Medical Decision Making, Vol. 38, No. 1_suppl, 01.04.2018, p. 66S-77S.

Research output: Contribution to journalArticle

Schechter, Clyde B. ; Near, Aimee M. ; Jayasekera, Jinani ; Chandler, Young ; Mandelblatt, Jeanne S. / Structure, Function, and Applications of the Georgetown–Einstein (GE) Breast Cancer Simulation Model. In: Medical Decision Making. 2018 ; Vol. 38, No. 1_suppl. pp. 66S-77S.
@article{4a5e533ec9704963a591f21d3ebd4a78,
title = "Structure, Function, and Applications of the Georgetown–Einstein (GE) Breast Cancer Simulation Model",
abstract = "Background. The Georgetown University-Albert Einstein College of Medicine breast cancer simulation model (Model GE) has evolved over time in structure and function to reflect advances in knowledge about breast cancer, improvements in early detection and treatment technology, and progress in computing resources. This article describes the model and provides examples of model applications. Methods. The model is a discrete events microsimulation of single-life histories of women from multiple birth cohorts. Events are simulated in the absence of screening and treatment, and interventions are then applied to assess their impact on population breast cancer trends. The model accommodates differences in natural history associated with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) biomarkers, as well as conventional breast cancer risk factors. The approach for simulating breast cancer natural history is phenomenological, relying on dates, stage, and age of clinical and screen detection for a tumor molecular subtype without explicitly modeling tumor growth. The inputs to the model are regularly updated to reflect current practice. Numerous technical modifications, including the use of object-oriented programming (C++), and more efficient algorithms, along with hardware advances, have increased program efficiency permitting simulations of large samples. Results. The model results consistently match key temporal trends in US breast cancer incidence and mortality. Conclusion. The model has been used in collaboration with other CISNET models to assess cancer control policies and will be applied to evaluate clinical trial design, recurrence risk, and polygenic risk-based screening.",
keywords = "breast cancer, simulation modeling",
author = "Schechter, {Clyde B.} and Near, {Aimee M.} and Jinani Jayasekera and Young Chandler and Mandelblatt, {Jeanne S.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1177/0272989X17698685",
language = "English (US)",
volume = "38",
pages = "66S--77S",
journal = "Medical Decision Making",
issn = "0272-989X",
publisher = "SAGE Publications Inc.",
number = "1_suppl",

}

TY - JOUR

T1 - Structure, Function, and Applications of the Georgetown–Einstein (GE) Breast Cancer Simulation Model

AU - Schechter, Clyde B.

AU - Near, Aimee M.

AU - Jayasekera, Jinani

AU - Chandler, Young

AU - Mandelblatt, Jeanne S.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background. The Georgetown University-Albert Einstein College of Medicine breast cancer simulation model (Model GE) has evolved over time in structure and function to reflect advances in knowledge about breast cancer, improvements in early detection and treatment technology, and progress in computing resources. This article describes the model and provides examples of model applications. Methods. The model is a discrete events microsimulation of single-life histories of women from multiple birth cohorts. Events are simulated in the absence of screening and treatment, and interventions are then applied to assess their impact on population breast cancer trends. The model accommodates differences in natural history associated with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) biomarkers, as well as conventional breast cancer risk factors. The approach for simulating breast cancer natural history is phenomenological, relying on dates, stage, and age of clinical and screen detection for a tumor molecular subtype without explicitly modeling tumor growth. The inputs to the model are regularly updated to reflect current practice. Numerous technical modifications, including the use of object-oriented programming (C++), and more efficient algorithms, along with hardware advances, have increased program efficiency permitting simulations of large samples. Results. The model results consistently match key temporal trends in US breast cancer incidence and mortality. Conclusion. The model has been used in collaboration with other CISNET models to assess cancer control policies and will be applied to evaluate clinical trial design, recurrence risk, and polygenic risk-based screening.

AB - Background. The Georgetown University-Albert Einstein College of Medicine breast cancer simulation model (Model GE) has evolved over time in structure and function to reflect advances in knowledge about breast cancer, improvements in early detection and treatment technology, and progress in computing resources. This article describes the model and provides examples of model applications. Methods. The model is a discrete events microsimulation of single-life histories of women from multiple birth cohorts. Events are simulated in the absence of screening and treatment, and interventions are then applied to assess their impact on population breast cancer trends. The model accommodates differences in natural history associated with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) biomarkers, as well as conventional breast cancer risk factors. The approach for simulating breast cancer natural history is phenomenological, relying on dates, stage, and age of clinical and screen detection for a tumor molecular subtype without explicitly modeling tumor growth. The inputs to the model are regularly updated to reflect current practice. Numerous technical modifications, including the use of object-oriented programming (C++), and more efficient algorithms, along with hardware advances, have increased program efficiency permitting simulations of large samples. Results. The model results consistently match key temporal trends in US breast cancer incidence and mortality. Conclusion. The model has been used in collaboration with other CISNET models to assess cancer control policies and will be applied to evaluate clinical trial design, recurrence risk, and polygenic risk-based screening.

KW - breast cancer

KW - simulation modeling

UR - http://www.scopus.com/inward/record.url?scp=85040637440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040637440&partnerID=8YFLogxK

U2 - 10.1177/0272989X17698685

DO - 10.1177/0272989X17698685

M3 - Article

VL - 38

SP - 66S-77S

JO - Medical Decision Making

JF - Medical Decision Making

SN - 0272-989X

IS - 1_suppl

ER -